Summary
Himalaya Nutravedics India IPO would open for subscription on 22 September 2026 and close on 24 September 2026. The price band for the company’s IPO is ₹100-₹106, and the total offer size is ₹26.50 crore.
The firm manufactures and distributes Ayurvedic and nutraceutical formulations, including capsules, tablets, liquid orals, and medicated oils. The lot size is 1,200 shares, and the minimum application for a retail individual should be at least 2 lots (2,400 shares), which would require an investment of ₹2,54,400.
The maximum retail investment would also be ₹2,54,400. For HNIs, the minimum investment would be ₹3,81,600 for 3 lots of 3,600 shares, and the maximum would be ₹8,90,400 for 7 lots of 8,400 shares.
The Himalaya Nutravedics India IPO is scheduled to commence on 22nd September 2026 and conclude on 24th September 2026. The offer size will be around ₹26.50 crore, and the price band will be ₹100-₹106 per share.
The IPO listing is slated for the BSE SME segment on 29th September 2026, and the allotment will be declared on 25th September 2026. The lot size for this IPO is 1,200 shares.
The applicants need to bid in multiples of 1,200 shares. The minimum and maximum allotments for the retail category would be 2,400 shares (2 lots)each, amounting to ₹2,54,400. The allotment for the S-HNI category will be a minimum of 3,600 shares (3 lots), amounting to ₹3,81,600, and a maximum of 8,400 shares (7 lots), amounting to ₹8,90,400, and for the B-HNI category, 9,600 shares (8 Lots), amounting to ₹10,17,600.
Himalaya Nutravedics India IPO Key Details
Here is a quick look at the important details of the Himalaya Nutravedics India IPO:
| IPO Open Date | 22 September, 2026 |
| Close Date | 24 September, 2026 |
| Face value | ₹10 per share |
| Price Band | ₹100 to ₹106 |
| Issue price | – |
| IPO Lot Size | 1,200 shares |
| Offer for sale | – |
| Fresh issue | 23,73,600 shares (~ ₹25 cr) |
| Issue Type | Bookbuilding IPO |
| Listing at | BSE SME |
| Total Issue Size (₹ Crore) | 24,99,600 shares (~₹26 cr) |
| Minimum Investment | ₹2,54,400 (2,400 shares) |
Himalaya Nutravedics India IPO Timeline
The key dates for the Himalaya Nutravedics India IPO are given below:
| Bidding Opens | 22 September, 2026 |
| Bidding Closes | 24 September, 2026 |
| Allotment Planned For | 25 September, 2026 |
| Refunds Start On | 28 September, 2026 |
| Share Credit to Demat | 28 September, 2026 |
| Listing Scheduled | 29 September, 2026 |
| Cut-off for UPI mandate | 24 September, 2026 5:00 PM |
Himalaya Nutravedics India Key Performance Indicators (KPIs)
Himalaya Nutravedics India IPO KPIs are presented in the following table:
| KPIs | FY 2026 | FY 2025 | FY 2024 |
| ROE (%) | 63.87% | 55.02% | 37.29% |
| ROCE (%) | 36.41% | 30.18% | 17.00% |
| Debt-Equity (times) | 0.31 | 0.26 | 2.39 |
| RoNW (%) | 45.12% | 33.08% | 31.77% |
| Net PAT Margin (%) | 17.16% | 10.63% | 2.95% |
| EBITDA Margin (%) | 18.82% | 14.24% | 6.48% |
| Price Book Value | 3.97 |
Himalaya Nutravedics India IPO Financials
Here is an overview of the company’s financial figures:
| Period | FY 2026 | FY 2025 | FY 2024 |
| Total Assets | 2,441.80 | 1,081.65 | 609.17 |
| Revenue from operations | 4,306.75 | 2,099.65 | 1,442.56 |
| Profit After Tax | 738.97 | 223.18 | 42.60 |
Himalaya Nutravedics India IPO Subscription Status
Subscription Details Not Yet Available
Subscription information will be displayed once the bidding process starts.
Bidding is open from 10:00 AM to 5:00 PM on public issue days.
Himalaya Nutravedics India IPO Grey Market Premium
The listing date for the Himalaya Nutravedics India IPO is expected on 29, September 2026, with a price range of ₹100- ₹106 per equity share. Grey market premiums (GMPs) can fluctuate frequently because they are unofficial.
| GMP Date | GMP | Trend Direction | Est. Listing Price (cap price + GMP) | Last Updated |
|---|---|---|---|---|
| 18-09-2026 | ₹0 ─ | Initial | ₹106 (0.00%) | 18-Sep-2026 13:00 |
Note: GMP represents sentiment in the unofficial market and should not be considered an indication of assured listing returns.
Himalaya Nutravedics India IPO Reservation
The share allocation for each investor category is outlined below:
| Investor Category | Reservation |
| Market Maker | 1,26,000 shares |
| QIB | 11,84,400 shares |
| NIIs | 3,56,400 shares |
| Retail Investors | 8,32,800 shares |
| Total Shares | 24,99,600 shares |
Himalaya Nutravedics India IPO Lot Size
The applicable lot sizes for different investor categories are as follows:
| Application Type | Lots | Shares | Amount |
| Individual Investor – Minimum | 2 | 2,400 | ₹2,54,400 |
| Individual Investor – Maximum | 2 | 2,400 | ₹2,54,400 |
| S-HNI Minimum | 3 | 3,600 | ₹3,81,600 |
| S-HNI Maximum | 7 | 8,400 | ₹8,90,400 |
| B-HNI Minimum | 8 | 9,600 | ₹10,17,600 |
Himalaya Nutravedics India IPO Anchor Investors
The allotment status of the Himalaya Nutravedics India IPO is currently not yet available. As a result, information related to anchor bidding, share allocation, investment value, and lock-in periods will be added once it is disclosed.
Himalaya Nutravedics India IPO Prospectus
For more information on the Himalaya Nutravedics India IPO, check the links below:
About Himalaya Nutravedics India IPO
Incorporation: 2022
Managing Director: Rohit Asawa
Himalaya Nutravedics India is involved in the development, manufacture, marketing and distribution of Ayurvedic and nutraceutical products. The company specialises in products that promote health and wellness based on the Ayurvedic philosophy, using advanced manufacturing techniques.
It has a range of products, including various health and wellness formulations in tablet, capsule, liquid, and medicated oil forms. The company serves its clients through various distribution channels and focuses on consistently delivering quality products.
| Issue Registrar | Kfin Technologies Ltd. |
| Lead Manager | Nirbhay Capital Services Pvt. Ltd. |
Himalaya Nutravedics India IPO Objectives
Funds received from the IPO will be directed towards the following purposes:
| Particulars | Amount (in ₹ Lakhs) |
| Funding working capital requirements | 1,375 |
| Business development and digital marketing activities | 750 |
| General corporate purposes |
Strengths of Himalaya Nutravedics India IPO
There have been some improvements in the scale and profitability of Himalaya Nutravedics India; at the same time, the product line and distribution channels have opened up numerous growth opportunities. These strengths demonstrate important business parameters that investors can evaluate.
- High Revenue Growth: Revenues from operations have grown from ₹1,442.56 lakhs in FY24 to ₹4,306.75 lakhs in FY26. This is more than a tripling over two years. The rapid increase demonstrates that the company has grown its sales and expanded its markets.
- Diversified Product Range: The company produces capsules, tablets, liquids, and medicated oils. The product range focuses on digestive, immune, metabolic, pain management, and women’s wellness. The diversified product range enables the company to cater to a wide range of healthcare and wellness needs.
- Diverse Business Channels for Generating Revenue: The company generates revenue from its own Ayurvedic and nutraceutical brands as well as from third-party contract manufacturing. Thus, the company earns revenue through multiple business channels. The combination of both would enable the company to leverage its manufacturing capabilities while expanding its customer base.
- Expansion in Distribution Network: The distribution network of Himalaya Nutrivedics has been expanded to cover multiple Indian states. There is a diverse distribution network in place to market the company’s products, enabling it to reach various customers across India.
Risks of Himalaya Nutravedics India IPO
The firm has shown growth in its operations; however, investors should assess the risks and concentrations affecting revenue, supply chain continuity, and profits. These risks are:
- Customer Concentration Risk: The firm’s top 10 customers made up 81.24% of the revenue from operations in FY26 compared to 86.97% in FY25 and 84.19% in FY24. The high risk of concentration implies that losing major customers and a reduction in orders will affect the firm’s revenue. Lack of long-term agreements between customers and the firm is an added risk.
- High Dependency on Ayurvedic Products: Ayurvedic products accounted for 94.57% of revenue from operations in FY26, up from 92.09% in FY25 and 79.27% in FY24. The high concentration risk implies that changes in the market demand for the products may affect the firm.
- Single Manufacturing Facility: The firm’s production process is carried out at a single facility in Hyderabad, Telangana. Any operational or other local issue might hamper manufacturing and product availability. In addition, it is a leased facility and hence dependent on it.
- Risk due to Supplier Concentration: A significant share of the raw materials used in Himalaya Nutravedics products is sourced from the top 10 suppliers, with no long-term agreements in place to ensure supply. Any change in the supply chain can increase procurement costs and hamper the production process.
- Risk associated with Trademarks: Himalaya Nutravedics has applied for trademarks which are currently under opposition. Any negative decision regarding them might necessitate changes in the use of trademarks. This is especially important for a company that works in consumer healthcare and wellness products.
Himalaya Nutravedics India IPO Review
Himalaya Nutravedics India Limited IPO is a chance to look into a firm working in the Ayurvedic and nutraceutical products business. It earned revenue from operations of ₹4,306.75 lakhs in FY26, compared with ₹2,099.65 lakhs in FY25.
The firm produces tablets, capsules, liquids, and medicated oils and also engages in third-party manufacturing. The business has concentration in some areas; its top 10 customers account for 81.24% of the revenue in FY26.
The Ayurvedic products comprised 94.57% of its revenue in the same period. It has production concentration in a single plant based in Hyderabad. This IPO thus consists of high financial growth, along with a focus on customers, products, and manufacturing.
Other Recent IPO List
Stay updated on upcoming IPOs in India and explore new investment opportunities.
| Shakti Polytarp IPO | Quanto Agroworld IPO |
| Sonaselection Indian IPO | Jindal Supreme India IPO |
| Hero Motors IPO | National Stock Exchange IPO |
| Manika Plastech IPO | Rentomojo IPO |
Himalaya Nutravedics India IPO FAQs
Himalaya Nutravedics India IPO is the public issue of Himalaya Nutravedics India. The company belongs to the Ayurvedic & nutraceutical products segment. The products under its umbrella include tablets, capsules, liquids & medicated oils.
Investors can apply for the IPO through their stockbroker or through any approved online IPO portal. Investors usually have the option to apply for the IPO through the ASBA route via banks.
The IPO has its share of growth drivers and risks. Customer concentration and Ayurvedic products are critical elements to look at here.
There is no way to determine IPO returns in advance because they depend on the listing price, which in turn depends on market conditions and investor demand. The IPO price range is ₹100 to ₹106 per share.
The IPO of Himalaya Nutravedics India will commence on 22 September 2026. The subscription window is anticipated to continue till 24 September 2026. Investors can bid for shares within the IPO subscription window.
The IPO lot size is 1,200 shares. Retail investors must apply for a minimum of 2 lots, or 2,400 shares, requiring ₹2,54,400 at the upper price band of ₹106 per share.
The date for the determination of allotment of shares for the IPO is scheduled for 25 September 2026. The allotment is dependent upon the number of subscriptions and allocation rules. Investors can enquire about their allotments through the registrar or the exchange portal.
The Himalaya Nutravedics India IPO is slated to list on 29 September 2026. The listing will take place on the BSE SME platform. The market price after listing is to be decided.
